2022-04-25 16:00Financial Performance - The company's revenue for Q1 2022 reached ¥8,474,419,333.59, representing a year-on-year increase of 71.18%[6] - Net profit attributable to shareholders was ¥1,642,947,345.12, reflecting a growth of 9.54% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥1,714,144,938.66, which is an increase of 106.52% year-on-year[6] - Adjusted net profit under non-IFRS standards was ¥2,052,645,414.94, up by 85.82% from the previous year[6] - Total revenue for Q1 2022 reached ¥8,474,419,333.59, a 71.5% increase from ¥4,950,479,646.73 in Q1 2021[22] - Net profit for Q1 2022 was ¥1,655,950,521.89, up 9.8% from ¥1,507,104,723.57 in Q1 2021[22] - Operating profit for Q1 2022 was ¥2,004,959,729.24, compared to ¥1,697,539,566.19 in Q1 2021, reflecting a growth of 18.1%[22] - Basic earnings per share for Q1 2022 was ¥0.56, up from ¥0.52 in Q1 2021[23] Revenue Breakdown by Segment - The chemistry segment (WuXi Chemistry) generated revenue of RMB 611,796.51 million, up 102.11% from RMB 302,699.57 million in Q1 2021, with small molecule drug discovery services contributing RMB 174,486.09 million, a 46.62% increase[11][12] - The testing segment (WuXi Testing) reported revenue of RMB 127,938.81 million, a 31.70% increase from RMB 97,144.43 million in the same period last year, with laboratory analysis and testing services growing by 39.85%[12] - The biology segment (WuXi Biology) achieved revenue of RMB 53,261.22 million, reflecting a 26.17% increase from RMB 42,213.50 million in Q1 2021, with new molecular types and biopharmaceutical-related revenue growing by 110%[12] - The CTDMO business (WuXi ATU) generated revenue of RMB 29,864.80 million, a 36.99% increase from RMB 21,800.16 million in Q1 2021, with 74 projects receiving development and production services[12][13] - The domestic new drug development services (WuXi DDSU) reported revenue of RMB 24,062.85 million, down 21.57% from RMB 30,680.69 million in the previous year, due to business upgrades to meet higher client demands[13] Cash Flow and Assets - The net cash flow from operating activities was ¥497,469,053.50, showing a decrease of 25.62% compared to the same period last year[6] - The total assets as of March 31, 2022, amounted to ¥57,582,930,874.69, a 4.45% increase from the previous year[7] - The total current assets as of March 31, 2022, amount to ¥23,039,625,152.46, an increase from ¥21,985,648,602.33 in the previous year[20] - The company's cash and cash equivalents decreased to ¥7,026,897,217.80 from ¥8,238,772,782.53 year-over-year[19] - The total liabilities as of March 31, 2022, are ¥16,935,154,066.16, compared to ¥16,369,925,768.22 in the previous year[20] - The company reported a significant increase in accounts receivable, rising to ¥6,389,675,898.80 from ¥4,619,550,091.65[19] - The inventory as of March 31, 2022, is ¥6,414,769,393.91, compared to ¥5,905,005,712.92 in the previous year[19] Operational Efficiency and Strategy - The company continues to enhance its CRDMO and CTDMO business strategies to improve operational efficiency and capacity utilization[9] - The increase in revenue is attributed to the optimization of operational efficiency and the realization of scale effects[9] - The company completed over 90,000 custom compound syntheses in Q1 2022, enhancing early-stage small molecule drug development for clients[12] - The company expects to achieve a revenue growth of 63-65% in Q2 2022, contingent on the control of the COVID-19 situation in Shanghai and stable global pharmaceutical industry conditions[13] - The company launched the TESSA™ technology for scalable production of adeno-associated viruses (AAV), which is reported to produce AAV at ten times the efficiency of plasmid methods[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 206,649[14] - HKSCC NOMINEES LIMITED holds 392,128,463 shares, representing 13.27% of total shares[14] Research and Development - Research and development expenses increased to ¥280,042,477.39 in Q1 2022, up 37% from ¥204,576,017.34 in Q1 2021[22] - The company has a total of 1,808 new drug molecules in its chemistry service projects, with 49 in Phase III, 271 in Phase II, and 1,446 in Phase I and preclinical stages[12]